Sanofi
SNY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.31 | 0.06 | 0.14 | -0.84 |
| FCF Yield | 0.00% | 0.00% | 1.65% | 0.00% |
| EV / EBITDA | 26.30 | 57.22 | 50.37 | 226.00 |
| Quality | ||||
| ROIC | 2.75% | 1.20% | 1.66% | 0.53% |
| Gross Margin | 74.09% | 72.13% | 72.76% | 70.24% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -2.66% | -2.22% | -1.78% | -1.87% |
| Free Cash Flow Growth | 0.00% | -100.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 3.05 | 3.67 | 4.71 | 18.59 |
| Interest Coverage | 15.96 | 7.32 | 10.73 | 1.90 |
| Efficiency | ||||
| Inventory Turnover | 0.14 | 0.31 | 0.13 | 0.24 |
| Cash Conversion Cycle | 69.37 | 145.30 | 11.08 | 199.86 |